Neurogene Inc.
NGNE
$15.22
-$0.29-1.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 32.04% | 25.96% | 40.32% | 52.54% | 30.80% |
| Gross Profit | -32.04% | -25.96% | -40.32% | -43.58% | -30.80% |
| SG&A Expenses | 55.77% | 141.86% | 63.16% | 133.63% | 90.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.69% | 46.01% | 45.74% | 67.19% | 43.37% |
| Operating Income | -38.69% | -46.01% | -45.74% | -59.84% | -43.37% |
| Income Before Tax | -33.84% | -918.88% | -38.69% | -55.92% | -37.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.84% | -918.88% | -38.69% | -55.92% | -37.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.84% | -918.88% | -38.69% | -55.92% | -37.98% |
| EBIT | -38.69% | -46.01% | -45.74% | -59.84% | -43.37% |
| EBITDA | -40.83% | -48.97% | -48.52% | -64.08% | -46.21% |
| EPS Basic | -7.75% | -101.23% | 96.35% | 95.91% | 96.46% |
| Normalized Basic EPS | -8.32% | 95.39% | 96.35% | 95.91% | 96.48% |
| EPS Diluted | -7.75% | -133.21% | 96.35% | 95.91% | 96.46% |
| Normalized Diluted EPS | -8.32% | -24.11% | 96.35% | 95.91% | 96.48% |
| Average Basic Shares Outstanding | 24.21% | 2,927.90% | 3,698.66% | 3,711.36% | 3,798.45% |
| Average Diluted Shares Outstanding | 24.21% | 12.52% | 3,698.66% | 3,711.36% | 3,798.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |